Full-Time

Medical Science Liaison

Oncology

Posted on 4/9/2025

Amplity

Amplity

1-10 employees

Database of de-identified medical records

No salary listed

Mid, Senior

Remote in Spain

Candidates must be based in Spain.

Category
Physicians & Surgeons
Medical, Clinical & Veterinary
Connection
Connection
Connection
logo

Get referrals →

You have ways to get a Amplity referral from your network.

💡

Applications through a referral are 3x more likely to get an interview!

Requirements
  • An advanced doctoral degree (MD, PhD, Pharm D) is preferred
  • Relevant therapeutic area knowledge in the field of oncology (experience within gastrointestinal cancer, GEP-NETs, radiopharmaceutical therapies is a plus)
  • Fluency in English and Spanish
  • 3+ years of previous industry medical affairs experience required, preferably in MSL and/or headquartered based medical affairs role and clinical trial background
  • Demonstrable experience in building and maintaining relationships with KOLs
  • Ability to effectively communicate and assimilate scientific and clinical data to the relevant audience
  • Willing and able to travel internationally, up to ~ 70% of time
Responsibilities
  • Building and developing enduring relationships with HCPs, patient advocacy groups, professional societies, and institutions, creating constructive cross-functional partnerships with internal and external stakeholders
  • Serving as a primary interface between our client and clinical trial sites across all development programs, working closely with Clinical Development & Clinical Operations
  • Advising and participating in the planning and set-up of clinical studies
  • Representing our client at select scientific congresses and professional society meetings
  • Sharing important clinical and scientific insights that you have gathered from fieldwork to cross-functional teams
  • Acting as an internal and external scientific expert
  • Adhering to compliance requirements
  • Supporting investigator-initiated studies
Desired Qualifications
  • Post graduate therapeutic area experience is preferred
  • Biotech experience is a plus!

Amplity focuses on transforming medical records into actionable data for healthcare providers and researchers. The company compiles de-identified medical records into a comprehensive database that can be searched for various elements such as diseases, medications, and devices. This database includes millions of records from diverse specialties across all 50 states, allowing users to gain insights into patient conditions and their interactions with healthcare professionals. Unlike competitors, Amplity emphasizes providing customized access to real-world healthcare outcomes, enabling clients to make informed decisions based on detailed narrative data. The company's goal is to enhance understanding of healthcare dynamics through accessible and relevant data.

Company Size

1-10

Company Stage

Debt Financing

Total Funding

$102.5M

Headquarters

Santa Cruz, California

Founded

2010

Simplify Jobs

Simplify's Take

What believers are saying

  • Amplity's AI-driven platform enhances decision-making during critical drug launch periods.
  • The merger with Lynx expands Amplity's service offerings and market reach.
  • Chris Baker's leadership strengthens Amplity's data-driven strategies in biopharmaceuticals.

What critics are saying

  • Underutilization of biomarker testing may impact Amplity's precision medicine reputation.
  • Integration challenges from the Lynx merger could disrupt operations and client relationships.
  • Reliance on AI platforms may face issues with data accuracy affecting decision-making.

What makes Amplity unique

  • Amplity leverages AI-driven platforms for real-time insights during drug launches.
  • Their proprietary database analyzes over 70 million electronic medical records for healthcare insights.
  • Amplity addresses social determinants of health to improve healthcare equity and outcomes.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

Unlimited Paid Time Off

Company News

PR Newswire
Jun 7th, 2024
Amplity Health Study Identifies Major Gaps In Biomarker Testing And Targeted Therapy Use In Non-Small Cell Lung Cancer In The United States

Research presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting shows how the Amplity Health Insights™ Real-World Database enhances understanding of clinical decision-makingLANGHORNE, Pa., June 7, 2024 /PRNewswire/ -- Using point-of-care real-world data to analyze patterns, Amplity Health, a contract sales and medical outsourcing partner, found that biomarker testing for patients with non-small cell lung cancer (NSCLC) in the United States is significantly underutilized. Presented on June 3 at the 2024 ASCO Annual Meeting in Chicago, "Biomarker Testing and Targeted Therapy Use Among Patients With Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database," highlights critical gaps in testing practices and underscores the need for improved diagnostic strategies.Melanie Jardim, PhD, an Amplity Health executive and principal investigator of the study, shares “Biomarker Testing and Targeted Therapy Use Among Patients with Non-Small Cell Lung Cancer in the United States: An Analysis Using a Physician Notes Real-World Database,” at #ASCO24.By using natural language processing to examine more than 70 million records, this study showed that:A total of 61,018 patients were identified in the Amplity Health Insights ™ Database as having been diagnosed with NSCLC from October 2003 through November 2023™ Database as having been diagnosed with NSCLC from through Of the patients identified in the database as having NSCLC, only 13.4% were recorded as being biomarker testedOf the 6,387 patients with a mutation identified, only approximately 36% received an indicated treatment"Our data further suggest that even when biomarker testing is conducted, and actionable mutations are confirmed, many patients may not be receiving an appropriate targeted therapy," says Melanie Jardim, PhD, an Amplity Health executive and principal investigator of the study."When working with healthcare providers and clients, Amplity's goal is to help remove barriers and address social determinants related to biomarker testing and treatment, ultimately enhancing outcomes across all populations," adds Chris Baker, CEO of Amplity Health.Insights, Amplity's proprietary real-world qualitative database, analyzes over 70 million electronic medical records and effectively uncovers gaps in care. By leveraging data from community settings, combined with ethnicity and SDOH variables, Insights can be used to identify and address social inequities in healthcare. This enables pharmaceutical organizations to better align their strategies to ensure inclusive treatment and access for all patients.About Amplity InsightsAmplity Insights is Amplity Health's proprietary data offering, which provides solutions to clients' most elusive data challenges. By illuminating WHY healthcare practitioners make treatment decisions, our data solutions assist health economics and outcomes research, commercial, clinical, and data analytics teams in biopharma to rapidly move from hypothesis to impact. The mission of Amplity Insights is to maximize the utility of unstructured data by creating easy-to-use, state-of-the-art products and tools to empower leaders to serve patients better.This includes an unparalleled database, the Xplore platform, and the AI-driven search tool, AskX

S&P Global
Feb 21st, 2024
Amplity Health nets $102.5M incremental loan

Earlier this month, Amplity Health announced a merger with medical communications company Lynx.

PR Newswire
Feb 5th, 2024
Amplity Health Announces Leadership Changes

LANGHORNE, Pa., Feb. 5, 2024 /PRNewswire/ -- Amplity Health, a leading global contract medical and commercial organization, announced today that it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.Chris Baker joins Amplity Health as Chief Executive Officer."More and more, we are seeing a convergence between medical engagement and commercial engagement," says Griffith. "Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role

PR Newswire
Feb 5th, 2024
Amplity Health Announces Leadership Changes Usa - English

LANGHORNE, Pa., Feb. 5, 2024 /PRNewswire/ -- Amplity Health, a leading global contract medical and commercial organization, announced today that it has appointed Chris Baker to the position of Chief Executive Officer (CEO), effective immediately. Michael A. Griffith, Amplity founder and long-standing CEO, will transition to the role of Chairman of the Board of Directors as part of a deliberate succession plan. In this capacity, he will continue to support Baker and the leadership team, but with a primary focus on building the visibility and awareness of Amplity in the biopharmaceutical market.Chris Baker joins Amplity Health as Chief Executive Officer."More and more, we are seeing a convergence between medical engagement and commercial engagement," says Griffith. "Chris brings significant leadership experience in large pharma commercial operations, contract research, and data to this role

PR Newswire
Dec 6th, 2023
Amplity Health'S Breakthrough Ai-Driven Platform Offers Pharma Leaders Actionable Intel During Crucial Drug Launch Window

Survey by AskX delivers real-time, next-level insights with ease — both pre and post drug launchLANGHORNE, Pa., Dec. 6, 2023 /PRNewswire/ -- Contract Medical and Commercial Organization, Amplity Health has released a revolutionary AI-driven next best action solution that provides pharmaceutical and biopharmaceutical companies with an entirely new order of field insights that can be acted upon within the earliest days of a drug's release.The first six weeks of a launch can make or break a drug's future market performance. Traditional surveys and data collection practices can severely limit informed action during a critical time; shortcomings like clunky language and sluggish response times leave pharmaceutical and biopharmaceutical industry leaders lacking important insights while the clock ticks on their new medication's honeymoon period.Now, Amplity Health has completely flipped that script. Amplity's new Survey by AskX platform employs first-of-its-kind AI-powered capabilities that allow leadership to create customized field surveys and explore results using advanced application of generative AI on free-text responses.The Survey by AskX environment is entirely free-text based, meaning leaders can construct surveys and investigate their results in plain speak — without the need for extra time and personnel to make sense of survey findings. The results constitute a dramatic up-leveling in the consistency, punctuality, and value of field insights."Until now, there has never been a way for us to compliantly record the results of discussions between field reps and clinicians in free-text," said Joe Turner, Head of Amplity Insights. "Leaders not only had to poll their teams for anecdotal insights; they had to work to understand the results

INACTIVE